Sumitomo Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, an… Read more
Sumitomo Pharma Co. Ltd (SMDPY) - Net Assets
Latest net assets as of December 2025: $289.14 Billion USD
Based on the latest financial reports, Sumitomo Pharma Co. Ltd (SMDPY) has net assets worth $289.14 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($816.08 Billion) and total liabilities ($526.94 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $289.14 Billion |
| % of Total Assets | 35.43% |
| Annual Growth Rate | 1.13% |
| 5-Year Change | -73.85% |
| 10-Year Change | -62.04% |
| Growth Volatility | 30.87 |
Sumitomo Pharma Co. Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Sumitomo Pharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sumitomo Pharma Co. Ltd (2005–2025)
The table below shows the annual net assets of Sumitomo Pharma Co. Ltd from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $169.48 Billion | +8.55% |
| 2024-03-31 | $156.14 Billion | -61.62% |
| 2023-03-31 | $406.78 Billion | -39.61% |
| 2022-03-31 | $673.57 Billion | +3.92% |
| 2021-03-31 | $648.18 Billion | +2.54% |
| 2020-03-31 | $632.11 Billion | +26.89% |
| 2019-03-31 | $498.14 Billion | +10.03% |
| 2018-03-31 | $452.72 Billion | -1.72% |
| 2017-03-31 | $460.66 Billion | +3.18% |
| 2016-03-31 | $446.47 Billion | -1.01% |
| 2015-03-31 | $451.02 Billion | +13.17% |
| 2014-03-31 | $398.54 Billion | +14.11% |
| 2013-03-31 | $349.25 Billion | +9.40% |
| 2012-03-31 | $319.23 Billion | -1.47% |
| 2011-03-31 | $323.98 Billion | -5.68% |
| 2010-03-31 | $343.48 Billion | +5.85% |
| 2009-03-31 | $324.50 Billion | +1.93% |
| 2008-03-31 | $318.36 Billion | +4.04% |
| 2007-03-31 | $306.01 Billion | +6.02% |
| 2006-03-31 | $288.63 Billion | +113.12% |
| 2005-03-31 | $135.43 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sumitomo Pharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $46.78 Billion | 27.60% |
| Common Stock | $22.40 Billion | 13.22% |
| Other Comprehensive Income | $100.98 Billion | 59.58% |
| Total Equity | $169.48 Billion | 100.00% |
Sumitomo Pharma Co. Ltd Competitors by Market Cap
The table below lists competitors of Sumitomo Pharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
$876.35 Million |
|
AIMA Technology Group Co Ltd
SHG:603529
|
$876.40 Million |
|
Nos SGPS SA
LSE:0J1Z
|
$876.95 Million |
|
Bright Smart Securities & Commodities Group Limited
F:0BX
|
$877.25 Million |
|
Altarea
LSE:0IRK
|
$875.95 Million |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
$875.17 Million |
|
United Parks & Resorts Inc
NYSE:PRKS
|
$874.92 Million |
|
ARS Pharmaceuticals, Inc
NASDAQ:SPRY
|
$874.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sumitomo Pharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 156,063,000,000 to 169,479,000,000, a change of 13,416,000,000 (8.6%).
- Net income of 23,634,000,000 contributed positively to equity growth.
- Dividend payments of 3,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 56,033,000,000.
- Other factors increased equity by 45,818,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $23.63 Billion | +13.95% |
| Dividends Paid | $3.00 Million | -0.0% |
| Other Comprehensive Income | $-56.03 Billion | -33.06% |
| Other Changes | $45.82 Billion | +27.03% |
| Total Change | $- | 8.60% |
Book Value vs Market Value Analysis
This analysis compares Sumitomo Pharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | $815.50 | $4.78 | x |
| 2006-03-31 | $1024.10 | $4.78 | x |
| 2007-03-31 | $767.52 | $4.78 | x |
| 2008-03-31 | $800.58 | $4.78 | x |
| 2009-03-31 | $816.40 | $4.78 | x |
| 2010-03-31 | $864.51 | $4.78 | x |
| 2011-03-31 | $815.43 | $4.78 | x |
| 2012-03-31 | $803.47 | $4.78 | x |
| 2013-03-31 | $879.03 | $4.78 | x |
| 2014-03-31 | $1003.10 | $4.78 | x |
| 2015-03-31 | $1135.20 | $4.78 | x |
| 2016-03-31 | $1123.76 | $4.78 | x |
| 2017-03-31 | $1159.47 | $4.78 | x |
| 2018-03-31 | $1139.50 | $4.78 | x |
| 2019-03-31 | $1253.82 | $4.78 | x |
| 2020-03-31 | $1332.73 | $4.78 | x |
| 2021-03-31 | $1461.31 | $4.78 | x |
| 2022-03-31 | $1530.07 | $4.78 | x |
| 2023-03-31 | $1023.80 | $4.78 | x |
| 2024-03-31 | $392.82 | $4.78 | x |
| 2025-03-31 | $426.59 | $4.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sumitomo Pharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.93%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 4.38x
- Recent ROE (13.95%) is above the historical average (-4.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 5.14% | 3.95% | 0.87x | 1.50x | $-6.54 Billion |
| 2006 | 5.34% | 6.26% | 0.63x | 1.37x | $-13.40 Billion |
| 2007 | 7.41% | 8.65% | 0.68x | 1.25x | $-7.90 Billion |
| 2008 | 8.04% | 9.69% | 0.66x | 1.26x | $-6.23 Billion |
| 2009 | 6.16% | 7.57% | 0.67x | 1.21x | $-12.45 Billion |
| 2010 | 6.10% | 7.07% | 0.47x | 1.82x | $-13.39 Billion |
| 2011 | 5.18% | 4.43% | 0.64x | 1.82x | $-15.60 Billion |
| 2012 | 2.70% | 2.46% | 0.63x | 1.75x | $-23.29 Billion |
| 2013 | 2.88% | 2.89% | 0.57x | 1.74x | $-24.88 Billion |
| 2014 | 5.03% | 5.17% | 0.59x | 1.65x | $-19.79 Billion |
| 2015 | 3.42% | 4.16% | 0.52x | 1.58x | $-29.66 Billion |
| 2016 | 5.53% | 6.13% | 0.57x | 1.59x | $-19.95 Billion |
| 2017 | 6.29% | 7.04% | 0.52x | 1.72x | $-17.07 Billion |
| 2018 | 11.81% | 11.45% | 0.58x | 1.79x | $8.18 Billion |
| 2019 | 9.76% | 10.59% | 0.55x | 1.68x | $-1.19 Billion |
| 2020 | 7.70% | 8.44% | 0.39x | 2.37x | $-12.20 Billion |
| 2021 | 9.68% | 10.90% | 0.39x | 2.25x | $-1.84 Billion |
| 2022 | 9.28% | 10.07% | 0.43x | 2.15x | $-4.38 Billion |
| 2023 | -18.32% | -13.41% | 0.49x | 2.79x | $-115.19 Billion |
| 2024 | -201.82% | -100.13% | 0.35x | 5.81x | $-330.58 Billion |
| 2025 | 13.95% | 5.93% | 0.54x | 4.38x | $6.69 Billion |
Industry Comparison
This section compares Sumitomo Pharma Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sumitomo Pharma Co. Ltd (SMDPY) | $289.14 Billion | 5.14% | 1.82x | $876.03 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |